APA (7th ed.) Citation

Wang, F., Wang, Y., Xiong, B., Yang, Z., Wang, J., Yao, Y., . . . Yu, Z. Neoadjuvant pyrotinib and trastuzumab in HER2-positive breast cancer with no early response (NeoPaTHer): Efficacy, safety and biomarker analysis of a prospective, multicentre, response-adapted study. Nature Publishing Group.

Chicago Style (17th ed.) Citation

Wang, Fei, et al. Neoadjuvant Pyrotinib and Trastuzumab in HER2-positive Breast Cancer with No Early Response (NeoPaTHer): Efficacy, Safety and Biomarker Analysis of a Prospective, Multicentre, Response-adapted Study. Nature Publishing Group.

MLA (9th ed.) Citation

Wang, Fei, et al. Neoadjuvant Pyrotinib and Trastuzumab in HER2-positive Breast Cancer with No Early Response (NeoPaTHer): Efficacy, Safety and Biomarker Analysis of a Prospective, Multicentre, Response-adapted Study. Nature Publishing Group.